{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:45:54Z","timestamp":1780735554513,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Targeted approaches such as targeted axillary dissection (TAD) or sentinel lymph node biopsy (SLNB) showed false-negative rates of &lt; 10% compared with axillary lymph node dissection (ALND) in patients with nodal-positive breast cancer undergoing neoadjuvant systemic treatment (NAST). We aimed to evaluate real-world oncologic outcomes for different axillary staging techniques.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We identified nodal-positive breast cancer patients undergoing NAST from 2016 to 2021 from the state cancer registry of Baden-Wuerttemberg, Germany. Invasive disease-free survival (iDFS) was assessed using Kaplan\u2013Meier statistics and multivariate Cox regression models (adjusted for age, ypN stage, ypT stage, and tumor biologic subtype).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 2698 patients with a median follow-up of 24.7 months were identified: 2204 underwent ALND, 460 underwent SLNB (255 with \u2265 3 sentinel lymph nodes [SLNs] removed, 205 with 1\u20132 SLNs removed), and 34 underwent TAD. iDFS 3 years after surgery was 69.7% (ALND), 76.6% (SLNB with \u2265 3 SLNs removed), 76.7% (SLNB with &lt; 3 SLNs removed), and 78.7% (TAD). Multivariate Cox regression analysis showed no significant influence of different axillary staging techniques on iDFS (hazard ratio [HR] for SLNB with &lt; 3 SLNs removed 0.96, 95% confidence interval [CI] 0.62\u20131.50; HR for SLNB with \u2265 3 SLNs removed 0.86, 95% CI 0.56\u20131.3; HR for TAD 0.23, 95% CI 0.03\u20131.64; ALND reference), and for ypN+ (HR 1.92, 95% CI 1.49\u20132.49), triple-negative breast cancer (HR 2.35, 95% CI 1.80\u20133.06), and ypT3-4 (HR 2.93, 95% CI 2.02\u20134.24).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These real-world data provide evidence that patient selection for de-escalated axillary surgery for patients with nodal-positive breast cancer undergoing NAST was successfully adopted and no early alarm signals of iDFS detriment were detected.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-024-15292-y","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T21:01:42Z","timestamp":1715029302000},"page":"4381-4392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Oncologic Outcomes for Different Axillary Staging Techniques in Patients with Nodal-Positive Breast Cancer Undergoing Neoadjuvant Systematic Treatment: A Cancer Registry Study"],"prefix":"10.1245","volume":"31","author":[{"given":"Andr\u00e9","family":"Pfob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria B.","family":"Kokh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Surovtsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Morakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4684-9099","authenticated-orcid":false,"given":"Joerg","family":"Heil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"15292_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","volume":"19","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2018","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19:27\u201339.","journal-title":"Lancet Oncol."},{"key":"15292_CR2","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/bjs.5894","volume":"94","author":"JSD Mieog","year":"2007","unstructured":"Mieog JSD, Van Der Hage JA, Van De Velde CJH. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94:1189\u2013200.","journal-title":"Br J Surg."},{"key":"15292_CR3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/bjs\/znab145","volume":"108","author":"A Fancellu","year":"2021","unstructured":"Fancellu A, Houssami N, Sanna V, Porcu A, Ninniri C, Marinovich ML. Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: meta-analysis. Br J Surg. 2021;108:760\u20138.","journal-title":"Br J Surg."},{"key":"15292_CR4","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection versus no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918\u201326.","journal-title":"JAMA"},{"key":"15292_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609\u201318.","journal-title":"Lancet Oncol."},{"key":"15292_CR6","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial. JAMA. 2013;310:1455\u201361.","journal-title":"JAMA"},{"key":"15292_CR7","first-page":"18","volume":"24","author":"A Shirzadi","year":"2020","unstructured":"Shirzadi A, Mahmoodzadeh H, Qorbani M. Assessment of sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer in two subgroups: initially node negative and node positive converted to node negative: a systemic review and meta-analysis. J Res Med Sci. 2020;24:18.","journal-title":"J Res Med Sci."},{"key":"15292_CR8","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patientswith node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072\u20138.","journal-title":"J Clin Oncol."},{"issue":"5","key":"15292_CR9","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1097\/SLA.0000000000004572","volume":"276","author":"S Kuemmel","year":"2022","unstructured":"Kuemmel S, Heil J, Rueland A, Seiberling C, Harrach H, Schindowski D, et al. A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients. Ann Surg. 2022;276(5):e553\u201362.","journal-title":"Ann Surg."},{"key":"15292_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.6004\/jnccn.2018.0043","volume":"16","author":"SH Giordano","year":"2018","unstructured":"Giordano SH, Elias AD, Gradishar WJ. NCCN guidelines updates: breast cancer. J Natl Compr Canc Netw. 2018;16:605\u201310.","journal-title":"J Natl Compr Canc Netw."},{"key":"15292_CR11","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1055\/a-0646-4522","volume":"78","author":"A W\u00f6ckel","year":"2018","unstructured":"W\u00f6ckel A, Festl J, St\u00fcber T, Brust K, Stangl S, Heuschmann PU, et al. Interdisciplinary Screening, diagnosis, therapy and follow-up of breast cancer. Guideline of the DGGG and the DKG (S3-level, AWMF registry number 032\/045OL, December 2017): Part 1 with recommendations for the screening, diagnosis and therapy of breast Ca. Geburtshilfe Frauenheilkd. 2018;78:927\u201348.","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"15292_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S1470-2045(07)70278-4","volume":"8","author":"DN Krag","year":"2007","unstructured":"Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881\u20138.","journal-title":"Lancet Oncol."},{"key":"15292_CR13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927\u201333.","journal-title":"Lancet Oncol."},{"issue":"3","key":"15292_CR14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/SLA.0000000000003075","volume":"269","author":"JM Simons","year":"2019","unstructured":"Simons JM, van Nijnatten TJA, van der Pol CC, Luiten EJT, Koppert LB, Smidt ML. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis. Ann Surg. 2019;269(3):432\u201342.","journal-title":"Ann Surg."},{"key":"15292_CR15","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamasurg.2023.1772","volume":"158","author":"S Kuemmel","year":"2023","unstructured":"Kuemmel S, Heil J, Bruzas S, Breit E, Schindowski D, Harrach H, et al. Safety of targeted axillary dissection after neoadjuvant therapy in patients with node-positive breast cancer. JAMA Surg. 2023;158:807\u201315.","journal-title":"JAMA Surg."},{"key":"15292_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77\u201390.","journal-title":"Lancet Oncol."},{"key":"15292_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617\u201328.","journal-title":"N Engl J Med."},{"key":"15292_CR18","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147\u201359.","journal-title":"N Engl J Med."},{"key":"15292_CR19","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1245\/s10434-019-07809-7","volume":"26","author":"D Morency","year":"2019","unstructured":"Morency D, Dumitra S, Parvez E, Martel K, Basik M, Robidoux A, et al. Axillary lymph node ultrasound following neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: results from the SN FNAC study. Ann Surg Oncol. 2019;26:4337\u201345.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15292-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15292-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15292-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T20:16:32Z","timestamp":1718050592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15292-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["15292"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15292-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"5 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Andr\u00e9 Pfob, Daria B. Kokh, Irina Surovtsova, Fabian Riedel, Philipp Morakis, and Joerg Heil have no conflicts of interest to declare in relation to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"DISCLOSURE"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Ethical review and approval were waived for this study due to the de-identified information of the patients included in the BW database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ehtics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}